Watchlist
A lane for every drug and company you follow
What changed in the last 30 days and what is due in the next 90, on one timeline, with a daily or weekly email. A free account follows up to 5 items.
CompanyAbivaxnext in 57d
30 Sep 2026 · NewsAbivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 202621 Sep 2026 · NewsAbivax Presents Business Updates and First Half 2026 Financial Results21 Sep 2026 · NewsAbivax: 6-K filing10 Sep 2026 · Trial update[obefazimod] NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -110 Sep 2026 · Trial update[obefazimod] NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2Dec 2026 (month only) · in 57d · NCT06456593Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's D...
Drugobefazimodnext in 57d
30 Sep 2026 · NewsAbivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 202610 Sep 2026 · Trial updateNCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -110 Sep 2026 · Trial updateNCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2Dec 2026 (month only) · in 57d · NCT06456593Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's D...
Drugadalimumabnext in 27d
29 Sep 2026 · Trial updateNCT07845604: Precision Depression Adalimumab Trial28 Sep 2026 · NewsMeitheal Pharmaceuticals Announces FDA Approval of High-Concentration Formulation of YUSIMRY®, a Biosimilar to Humira®28 Sep 2026 · Trial updateNCT03895203: A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis24 Sep 2026 · Trial updateNCT07663526: Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®23 Sep 2026 · Trial updateNCT07836283: Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab22 Sep 2026 · Trial updateNCT06972446: A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis21 Sep 2026 · Trial updateNCT06849908: Baricitinib in the Treatment of Intestinal Behçet's Syndrome18 Sep 2026 · Trial updateNCT05313620: Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events17 Sep 2026 · Trial updateNCT07622771: Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical Trial15 Sep 2026 · Trial updateNCT06310837: Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis10 Sep 2026 · Trial updateNCT05640245: Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis10 Sep 2026 · Trial updateNCT07564505: A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease9 Sep 2026 · Trial updateNCT05322473: Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa9 Sep 2026 · Trial updateNCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease8 Sep 2026 · Trial updateNCT05108259: To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects8 Sep 2026 · Trial updateNCT07398651: Apremilast and Adalimumab in Psoriatic Arthritis PatientsNov 2026 (month only) · in 27d · NCT05874505Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uvei...30 Dec 2026 · in 86d · NCT07398651Apremilast and Adalimumab in Psoriatic Arthritis Patients31 Dec 2026 · in 87d · NCT05105347Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory...Jan 2027 (month only) · in 88d · NCT03153319Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI1 Jan 2027 · in 88d · NCT05535738Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
Trial updateNewsFinancialsPipelineReadout dueEarnings dueMonth only